|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4985 | (2013.01) |
| A61K 31/522 | (2006.01) | ||
| A61P 29/00 | (2006.01) | ||
| A61K 31/5025 | (2013.01) | ||
| A61K 31/519 | (2013.01) | ||
| C07D 473/06 | (2013.01) | ||
| A61K 31/522 | (2013.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61P 1/16 | (2018.01) | ||
| A61P 13/02 | (2018.01) | ||
| A61P 13/12 | (2018.01) | ||
| A61P 15/00 | (2018.01) | ||
| A61P 19/10 | (2018.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 25/28 | (2018.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 3/00 | (2018.01) | ||
| A61P 3/04 | (2018.01) | ||
| A61P 31/00 | (2018.01) | ||
| A61P 31/04 | (2018.01) | ||
| A61P 3/06 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 9/00 | (2018.01) | ||
| A61P 9/10 | (2018.01) | ||
| A61P 9/12 | (2018.01) | ||
| A61P 3/10 | (2018.01) |
| (11) | Number of the document | 2849754 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13722418.4 |
| Date of filing the European patent application | 2013-05-13 | |
| (97) | Date of publication of the European application | 2015-03-25 |
| (45) | Date of publication and mention of the grant of the patent | 2022-09-14 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2013/059828 |
| Date | 2013-05-13 |
| (87) | Number | WO 2013/171166 |
| Date | 2013-11-21 |
| (30) | Number | Date | Country code |
| 12167893 | 2012-05-14 | EP |
| (72) |
KLEIN, Thomas , DE
DAIBER, Andreas , DE
DUGI, Klaus , DE
MARK, Michael , DE
MUENZEL, Thomas , DE
|
| (73) |
Boehringer Ingelheim International GmbH ,
Binger Strasse 173, 55216 Ingelheim am Rhein,
DE
|
| (54) | LINAGLIPTIN, A XANTHINE DERIVATIVE AS DPP-4 INHIBITOR, FOR USE IN THE TREATMENT OF SIRS AND/OR SEPSIS |
| LINAGLIPTIN, A XANTHINE DERIVATIVE AS DPP-4 INHIBITOR, FOR USE IN THE TREATMENT OF SIRS AND/OR SEPSIS |